PD-L1 Quantitative by IHC
Also known as: PD-L1 Non-specific
Use
PD-L1 overexpression is associated with adverse prognosis in solid tumors, though specific prognosis varies among different tumor types. The utility of this PD-L1 (22C3) assay in predicting the response to therapy has not been determined for all tumor types, and standardized scoring methods do not exist for all tumor types.
Special Instructions
Not provided.
Limitations
The test was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the FDA. The utility of the PD-L1 (22C3) assay in predicting response to therapy across different tumor types is not fully determined, and standardized scoring methods do not exist for all types.
Methodology
Immunoassay (IHC)
Biomarkers
PD-L1
Protein
LOINC Codes
- 18781-5
- 48767-8 - Annotation comment Imp
- 74384-9 - Spec container Spec
- 55752-0 - Clinical info
- 39111-0 - Bdy site
- 66746-9 - Specimen type
- 50595-8 - Path Interp Spec-Imp
- 77202-0 - Laboratory comment Report
- 19139-5 - Pathologist name
- 19146-0 - Ref Lab Test Results
- 55229-9 - Immune stain study
- 8251-1 - Service Cmnt-Imp
- 62364-5 - Test performance info Spec
- 11502-2 - Laboratory report
Result Turnaround Time
1-2 days
Related Documents
For more information, please review the documents below
Specimen
Tissue (FFPE)
Volume
One tissue block or five unstained positively charged slides less than one month in age
Minimum Volume
At least three unstained slides sectioned at 4-5 microns
Container
Paraffin block or unstained positive charged slides
Collection Instructions
Paraffin block or unstained slides sectioned of no more than one month age.
Causes for Rejection
Slides sectioned greater than one month prior to test request
Other tests from different labs that may be relevant